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Primary open-angle glaucoma (POAG) is a blinding disease. Two important risk factors for this disease are a positive family
history and elevated intraocular pressure (IOP), which is also highly heritable. Genes found to date associated with IOP and
POAG are ABCA1, CAV1/CAV2, GAS7 and TMCO1. However, these genes explain only a small part of the heritability of IOP and
POAG.We performed a genome-wide association study of IOP in the population-based Rotterdam Study I and Rotterdam Study
II using single nucleotide polymorphisms (SNPs) imputed to 1000 Genomes. In this discovery cohort (n = 8105), we identiﬁed a
new locus associatedwith IOP. Themost signiﬁcantly associated SNPwas rs58073046 (β = 0.44, P-value = 1.87 × 10−8, minor allele
frequency = 0.12), within the gene ARHGEF12. Independent replication in ﬁve population-based studies (n = 7471) resulted in
an effect size in the same direction that was signiﬁcantly associated (β = 0.16, P-value = 0.04). The SNP was also signiﬁcantly
associated with POAG in two independent case–control studies [n = 1225 cases and n = 4117 controls; odds ratio (OR) = 1.53,
P-value = 1.99 × 10−8], especially with high-tension glaucoma (OR = 1.66, P-value = 2.81 × 10−9; for normal-tension glaucoma
OR = 1.29, P-value = 4.23 × 10−2). ARHGEF12 plays an important role in the RhoA/RhoA kinase pathway, which has been
implicated in IOP regulation. Furthermore, it binds to ABCA1 and links the ABCA1, CAV1/CAV2 and GAS7 pathway to Mendelian
POAG genes (MYOC, OPTN, WDR36). In conclusion, this study identiﬁed a novel association between IOP and ARHGEF12.
Introduction
Glaucoma is a heritable eye disease affecting the optic nerve,
which leads to irreversible visual ﬁeld loss and eventually to
blindness. Primary open-angle glaucoma (POAG) is the most
common formof glaucoma. Individualswith aﬁrst-degree family
member affected with POAG have a 10-fold increased risk of
developing the disease (1). Variants in MYOC, OPTN and WDR36
explain some familial forms of POAG (2–7). However, disease-
causing mutations in these genes are rare in POAG patients and
therefore explain only a small part of the overall heritability.
Genome-wide association studies (GWAS) have identiﬁed
CAV1/CAV2, TMCO1, SIX6 and CDKN2B-AS1 as POAG genes, and
recently ABCA1, AFAP1 and GMDS were added to the list (8–12).
Elevated intraocular pressure (IOP) is an important risk factor
for glaucoma and the target of glaucoma therapy is lowering the
IOP. IOP is highly heritable with heritability estimates ranging
between 0.29 and 0.67 (13,14). TMCO1, GAS7 and FAM125B were
implicated in IOP, as well as the CAV1/CAV2 region (12,15). The
International Glaucoma Genetics Consortium (IGGC) recently
published a meta-analysis of IOP, reporting four new genes for
IOP (FNDC3B, ABCA1, ABO and a region on chromosome 11.
p11.2 with many genes in it), and showed that one of the new
genes (ABCA1) also inﬂuences the risk of developing POAG (16).
This has shown that investigating the genetics of IOP is a fruitful
approach to discover genes related to POAG.
The IGGCmeta-analysis utilized data imputed to the HapMap
2 reference panel. In this study, we aimed to identify new genetic
variants associatedwith IOPusing 1000Genomes reference panel
to increase the number of variants analysed in the population-
based Rotterdam Study.
Results
After exclusion of 95 subjects with a history of IOP-lowering laser
or surgery, 8105 subjects were included in the meta-analysis of
the discovery cohorts [Rotterdam Study I (RS-I) and Rotterdam
Study II (RS-II)]. The demographics of all individual studies are
shown in Table 1. The inﬂation factor (λ) was 1.03 for RS-I and
1.01 for RS-II, indicating good control of population substruc-
tures. The λ of the meta-analysis was 1.04 (Supplementary
Material, Fig. S1). In the meta-analysis, three single nucleotide
polymorphisms (SNPs) reached genome-wide signiﬁcance
(Fig. 1). These three SNPs were located on chromosome 11q23.3
in the ARHGEF12 gene. The most signiﬁcantly associated SNP
was the intronic variant rs58073046 [β = 0.44, P-value = 1.87 × 10−8,
minor allele frequency (MAF) = 0.12; Fig. 2 and Table 2]. Since IOP
can be inﬂuenced by the central corneal thickness (CCT), we
adjusted for CCT. Adjustment for CCT was possible in only 25%
of the data set. In this small subset, by chance the effect of
rs58073046 on IOP without adjustment for CCT was smaller
(β = 0.34, P-value = 4.44 × 10−2, n = 2036). After adjustment for
CCT, the effect estimate was 0.36 and remained marginally sig-
niﬁcant despite the small sample size (P-value for effect of
rs58073046 on IOP corrected for CCT = 3.35 × 10−2, n = 2036).
When combining the results of the validation cohort,
rs58073046 was replicated (β = 0.16, P-value = 4.13 × 10−2, n = 7471;
Table 2). The effect estimates of each individual study are shown
in Figure 3. Figure 2 shows that 93 SNPs in the chromosome
11q23.3 region reached a P-value below 5.0 × 10−5 in the discovery
cohort. All 93 SNPs were included in the combinedmeta-analysis
of the discovery and replication cohorts (see Supplementary Ma-
terial, Table S1). The two most signiﬁcant associations are two
SNPs in linkage disequilibrium (pairwise correlation r2 is 1 in
1000 Genomes Pilot 1 in Northern Europeans) which has thus
similar effect sizes and P-values (rs58073046: β = 0.30, P-value =
6.12 × 10−8; rs11217863: β = 0.30 for the minor allele, P-value =
6.22 × 10−8; for all studies together). Twenty-four of the 93 SNPs
included in the combinedmeta-analysis are located in regulatory
elements, particularly at enhancers (16/24) and promoter ﬂank-
ing regions (7/24), and one at a CTCF-binding site, suggesting an
effect on IOP by altering regulation of ARHGEF12 or other genes.
Expression proﬁle of human ARHGEF12 was investigated
using UniGene, an expressed sequence tag (EST) database from
NCBI. Positive expressionwas found in various tissues, being par-
ticularly high in the eye, vascular tissue, ear, adipose tissue,
mouth, uterus and skin (Supplementary Material, Table S2).
Eye-speciﬁc expression of ARHGEF12 was examined through the
eye-centric genome browser, EyeBrowse, which showed that
ARHGEF12 is expressed in the cornea, lens, iris, trabecular mesh-
work, retina, optic nerve and human foetal eye (Supplementary
Material, Table S3a). Compared with other genes in the neigh-
bourhood (POU2F3 and TMEM136), ARHGEF12 presents the high-
est EST counts in the eye (Supplementary Material, Table S3b).
This ﬁnding is consistent with microarray data from the Ocular
Tissue Database in which the highest expression of ARHGEF12
occurred in the trabecular meshwork (Supplementary Material,
Table S4).
The most signiﬁcantly associated SNP (rs58073046) explained
0.4% (RS-I) and 0.3% (RS-II) of the variance in IOP (Table 3). The
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Figure 1.Manhattan plot of themeta-analysis of GWAS for IOP in the discovery phase (n = 8105). Eachdot represents a SNP. Theplot shows−log10-transformed P-values for
all SNPs. The upper black-dotted horizontal line represents the threshold of genome-wide signiﬁcance (P-value < 5.0 × 10−8); the lower black-dotted horizontal line
represents a P-value of 1 × 10−5.





RS-I RS-II RS-III BATS BMES Raine TEST
n included in analysis 6010 2095 2992 1152 1769 895 663
Mean age (SD) 69.2 (9.0) 64.8 (7.9) 57.2 (6.8) 20.1 (4.0) 64.0 (8.3) 20.0 (0.4) 25.6 (18.8)
% male 40 46 44 53 43 49 60
Mean IOP (SD) 14.7 (3.2) 14.2 (3.1) 13.6 (2.9) 15.8 (2.9) 16.1 (2.7) 14.9 (4.7) 15.8 (3.1)
n of participants with IOP-lowering medication 112 40 35 – 38 – –
n of participants with IOP-lowering laser/surgery 59 36 12 – 18 – –
BATS, Brisbane Adolescent Twins Study; BMES, Blue Mountains Eye Study; IOP, intraocular pressure; n, number of samples; RS, Rotterdam Study; SD, standard deviation;
TEST, Twins Eye Study in Tasmania.
Figure 2. Regional associationand recombinationplotof the 11q23.3 region in themeta-analysis of thediscovery cohorts. Plots are centredon rs58073046 (purplediamond), the
most signiﬁcantly associated single SNP in this region, andﬂanked by themeta‐analysis results for SNPs in the 400‐kb region surrounding it. SNPs are shaded according to their
pairwise correlation (r2) with rs58073046. The blue line represents the estimated recombination rates; the gene annotations are shown below the ﬁgure.
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explained phenotypic variance increased to 1.0% (RS-I) and 0.6%
(RS-II) by adding the 24 regulatory variants at 11q23.3, and to 2.2%
(RS-I) and 2.6% (RS-II) by adding all the other 11q23.3 variants
which reached a P-value below 5.0 × 10−5 in the discovery cohort,
but the differences in explained variance are not statistically sig-
niﬁcant between the models.
The SNP (rs58073046) was also genome-wide signiﬁcantly as-
sociated with POAG in 1225 cases and 4117 controls [odds ratio
(OR) = 1.53, P-value = 1.99 × 10−8; Table 4]. The association of
rs58073046 was stronger for high-tension glaucoma (HTG) (OR =
1.66, P-value = 2.81 × 10−9) than for normal-tension glaucoma
(NTG) (OR = 1.29, P-value = 4.23 × 10−2).
Figure 4 shows a network map of protein interactions created
using the Ingenuity Pathway Analysis (IPA) software. ARHGEF12
binds directly to ABCA1 and RhoAproteins, and interacts through
other proteins with genes implicated in POAG by GWAS (CAV1/
CAV2, GAS7) or linkage analysis (MYOC, OPTN and WDR36). No
evidence was found for interactions with protein products of
other known IOP genes such as ABO, TMCO1 or FNDC3B.
Discussion
The aimof this studywas to identify newgenetic variants that in-
ﬂuence IOP using GWAS data sets imputed to the 1000 Genomes
reference panel. We have identiﬁed a new region, chromosome
11q23.3, associated with IOP. The SNP rs58073046 is located in
ARHGEF12. This gene was previously associated with POAG, but
the ﬁndings did not replicate (8). The association of the region
with IOP is new.
Gharahkhani et al. (8) previously reported an association
between POAG and rs11827818 (OR 1.52, P-value = 9.2 × 10−9), an
intronic SNP located within the TMEM136 gene near to ARH-
GEF12, in 1155 cases and 1992 controls from the ANZRAG study.
We checked the association between the variant found by
Gharahkhani et al. and POAG in the Genetic Research in Isolated
Populations (GRIP)/Erasmus Rucphen Family (ERF) study consist-
ing of 110 POAG cases. Themagnitude for rs11827818was smaller
(OR 1.15 for overall glaucoma and OR 1.36 for HTG) than themag-
nitude of the most associated SNP rs58073046 observed in our
study (OR 1.46 for overall POAG and OR 1.79 for HTG). These two
SNPs (rs11827818 and rs58073046) are in partial linkage disequi-
librium (pairwise correlation r2 is 0.51 in 1000 Genomes Pilot 1
in Northern Europeans). Gharahkhani et al. used the genotyped
SNP rs2276035 within ARHGEF12 for replication in other POAG
case–control studies; however, this SNP did not clearly replicate.
In our GRIP/ERF study, rs2276035 was not associated with POAG
(OR 0.99 for overall POAG and OR 1.22 for those with HTG).
In our analysis of IOP, the SNP found by Gharahkhani et al.
(rs11827818) was associated with an increased mean IOP level
in our discovery cohorts but did not reach genome-wide signiﬁ-
cance (β = 0.30, P-value = 6.41 × 10−6). In our replication cohorts,
the effect of rs58073046 on IOP was heterogeneous between
studies, particularly in one small study (BATS) in which the
effect was in the opposite direction. The I2 for heterogeneity
was 41.5 in the combined analysis of all studies. However,
after removal of BATS, the heterogeneity I2 was 0.0 and the
P-value became 5.04 × 10−9. BATS is a relatively small and
younger sample, which might explain the failure to replicate
the ﬁndings. The effect estimates from all other replication
cohorts were in the same direction as that from our discovery
cohorts, although smaller in magnitude.
ARHGEF12 [Rho guanine nucleotide exchange factor (GEF)
12; previously known as Leukemia-Associated Rho Guanine
Nucleotide Exchange Factor or LARG] may regulate RhoAGTPases
(17). Rho proteins are important for numerous cellular processes.
Activation of RhoA protein will lead to the activation of ROCK, a
RhoA kinase. It has been shown that RhoA/RhoA kinase signal-
ling plays a role in regulation of trabecular meshwork plasticity,
ﬁbrogen activity and myoﬁbroblast activation (18). Activation of
RhoA proteins can also decrease the permeability of Schlemm’s
canal cells (19). This links ARHGEF12 to POAG as the regulation
of IOP is a balance between the production of aqueous humour
by the ciliary body and the outﬂow through the trabecular mesh-
work and Schlemm’s canal cells. The changes in trabecular
meshwork and Schlemm’s canal cells lead to an increased re-
sistance for the aqueous humour outﬂow and subsequently an
elevated IOP. ROCK-inhibitors can decrease IOP by inducing
Table 2. Summary of the discovery and replication ﬁndings of the genome-wide search for IOP-related genes using data imputed to the 1000
Genomes reference





(n = 15 576)
β SE P-value β SE P-value β SE P-value I2
rs58073046 11/120248493 g/a 0.12 0.44 0.08 1.87 × 10−8 0.16 0.08 4.13 × 10−2 0.30 0.06 6.22 × 10−8 41.6
A1, allele 1, the effect allele; A2, allele 2; β, effect size on IOP based on allele 1; Chr, chromosome; MAF, minor allele frequenty (=A1); I2, I2 for heterogeneity between all
samples; pos, position; SE, standard error; SNP, single nucleotide polymorphism.
Figure 3. Forest plot for rs58073046 (chromosome 11q23.3). For each study, the
square shows the β linear regression coefﬁcient or the average difference in IOP
for each additional copy of the minor allele (G) and the lines represent the
standard error of the estimate. BATS, Brisbane Adolescent Twins Study; BMES,
Blue Mountains Eye Study; RS, Rotterdam Study; TEST, Twins Eye Study in
Tasmania.
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relaxation of trabecular meshwork and ciliary body muscles and
seems to be a good new target for IOP-lowering therapy (20).
Interestingly, ARHGEF12 links the ABCA1, CAV1/CAV2 and
GAS7 genes, which has been previously associated with IOP as
well as with POAG, to Mendelian POAG genes (MYOC, OPTN and
WDR36). The ARHGEF12 gene interacts with ABCA1. ARHGEF12
can extend the half-life of the ABCA1 protein, by binding to
its C terminus and subsequently activating RhoA, which in turn
prevents ABCA1 degradation (21).ABCA1 plays a role in the trans-
port of different molecules across extra- and intra-cellular
membranes and the interference ofARHGEF12 in the degradation
of ABCA1 protein might extend the transportation of molecules.
ABCA1 is not the only glaucoma gene that has a role in the trans-
port of vesicles. CAV1, CAV2 and FAM125B have been also impli-
cated in vesicle transport (15).
In ﬂies, RhoGEF2 is the single homologue of mammalian ARH-
GEF1, ARHGEF11 and ARHGEF12, and has been extensively
studied in the context of tumorigenesis (22). Flies lacking
RhoGEF2 showed an early embryonic lethality (23,24), while over-
expression of this gene in the eye resulted in small eyes, ablation
of eye tissue, aberrant proliferation patterns, tissue morphology
and partially blocked differentiation (22). Overexpression of Rho1
GTPase results in a rough eye phenotype with reduced retinal
thickness (25), but in the presence of RhoGEF2, the retina thickness
is recovered (23), supporting the role of RhoGEF2 as upstream acti-
vator of Rho1 in the developing eye. No data about eyemorphology
or histology have been described in either knockout ﬂies or mice.
The absence of arhgef12 in mice leads to embryonic lethality
with incomplete penetrance, which might be explained by redun-
dancy of arhgef11 and arhgef12 (26). These ﬁndings suggest that
arhgef12 expression is required during eye and general develop-
ment and that its absence may impact animal viability.
POU2F3 is another gene in the region on chromosome 11. It is
a member of the POU domain family of transcription factors,
which regulate cell type-speciﬁc differentiation pathways.
POU2F3 speciﬁcally regulates differentiation of keratinocytes
(27). POU2AF1 is a POU class-associating factor and is associated
with CCT (28). Because IOP is related to CCT, we performed an
additional analysis with extra adjustment for CCT in the discov-
ery cohorts. Only a small subset of the discovery cohorts had CCT
data available; therefore, the association did not reach genome-
wide signiﬁcance after this additional adjustment. However,
the β was similar, suggesting that the signal of association on
chromosome 11 is independent of CCT.
TMEM136 (transmembrane protein 136) is the gene be-
tween ARHGEF12 and POU2F3. Compared with TMEM136 and
POU2F3, ARHGEF12 showed the highest expression in the eye
and particularly in the trabecular meshwork and ciliary body
Table 4. Result of the association of rs58073046 with POAG
Controls
(n)
All POAG HTG NTG
Cases (n) OR 95% CI P-value Cases (n) OR 95% CI P-value Cases (n) OR 95% CI P-value
ANZRAG 1992 1115 1.54 1.32–1.80 3.14 × 10−7 709 1.65 1.38–1.97 2.12 × 10−7 330 1.33 1.03–1.72 3.01 × 10−2
ERF/GRIP 2125 110 1.46 0.91–2.35 1.27 × 10−1 68 1.79 1.04–3.09 4.10 × 10−2 42 0.92 0.41–2.06 8.36 × 10−1
Meta-analysis 4117 1225 1.53 1.32–1.78 1.99 × 10−8 777 1.66 1.41–1.97 2.81 × 10−9 372 1.29 1.01–1.64 4.23 × 10−2
ANZRAG, Australian and New Zealand Registry of Advanced Glaucoma; CI, conﬁdence interval; ERF/GRIP, Erasmus Rucphen Family study and Genetic Research in
Isolated Populations; HTG, high-tension glaucoma; NTG, normal-tension glaucoma; OR, odds ratio; POAG, primary open-angle glaucoma.
Note that the sumof HTG andNTG is not equal to the total number of cases in the ANZRAG cohort, since peak IOPmeasureswere only available for 1039 of the 1155 cases.
The table shows the association result for all POAG, as well as for the subtypes HTG (IOP >21 mmHg) and NTG (IOP ≤21 mmHg).
Figure 4. Network map of protein–protein interactions between ARHGEF12 with
(A) previously known genes associated with IOP and glaucoma (ABCA1, CAV1/
CAV2, GAS7), and (B) known genes involved in familial forms of glaucoma
(MYOC, OPTN, WDR36). Map was built using Ingenuity Pathway Analysis. Solid
lines imply direct relationships between proteins (e.g. physical protein–protein
interaction or enzyme-substrate); dotted lines imply indirect functional
relationships, such as co-expression, phosphorylation/dephosphorylation,
activation/deactivation, transcription or inhibition. Proteins in bold correspond
to known glaucoma genes. Meaning of symbols is shown on the right side of
the ﬁgure.
Table 3. The explained variance of IOP in the Rotterdam Study I (RS-I) and Rotterdam Study II (RS-II)
RS-I RS-II
Explained variance (%) P-value Explained variance (%) P-value
Model 1 = rs58073046 0.4 0.3
Model 2 =model 1 + promotor ﬂanking region SNPs 0.6 0.28 0.4 0.89
Model 3 =model 2 + enhancers + CTCF binding site 1.0 0.19 0.6 0.82
Model 4 =model 3 + all other SNPs (93 in total) 2.2 0.06 2.6 0.16
Models with different predictors were tested and the P-value shows the P-value of the difference in explained variance for models 2–4 compared with model 1.
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(Supplementary Material, Tables S3b and S4). These ﬁndings, be-
sides its interaction with known POAG and IOP genes, are com-
patible with the view that ARHGEF12 is most likely the gene
causing the association signal. Nonetheless, further functional
studies focusing on eye phenotypes are needed to clarify the
role of chromosome 11q23.3 in the regulation of IOP and its inﬂu-
ence on the risk of glaucoma.
In summary, our meta-analysis of GWAS has identiﬁed a
new locus that may be important for the regulation of IOP and
the risk of glaucoma. ARHGEF12 is the most likely gene causing
the association signal. It plays a role in the RhoA/RhoA kinase
signalling which has been proven to be an important new target
for glaucoma therapy. Our study shows that investigating the
genetics of IOP is a fruitful way to elucidate the genetics of
glaucoma.
Materials and Methods
We performed a meta-analysis of GWAS in two discovery
cohorts—RS-I and RS-II—which are identical in population struc-
ture. Our replication cohorts include the Brisbane Adolescent
Twins Study (BATS), BlueMountains Eye Study (BMES), theWestern
Australian Pregnancy Cohort (Raine) Study, the RotterdamStudy III
(RS-III) andTwins Eye Study inTasmania (TEST). Next,we validated
our ﬁndings in the Australian and New Zealand Registry of Ad-
vancedGlaucoma (ANZRAG)andGRIP/ERFPOAGcase–control stud-
ies. All studies adhered to the tenets of the Declaration of Helsinki
and written, informed consent was obtained from all participants.
The Rotterdam Study
The Rotterdam Study is a population-based study established in
Rotterdam, The Netherlands (29). It consists of three cohorts. The
original cohort, RS-I, started in 1990 and includes 7983 subjects
aged 55 years and older. The second cohort, RS-II, was added in
2000 and includes 3011 subjects aged 55 years and older. The
last cohort, RS-III, includes 3932 subjects of 45 years of age and
older and started in 2006. In all three cohorts, IOP was measured
for both eyes with Goldmann applanation tonometry (Haag-
Streit, Bern, Switzerland). The measurement was done twice. If
the second measurement was different from the ﬁrst measure-
ment, a third measurement was performed and the median of
all three values was taken. A subset of participants from RS-I
underwent CCT measurements at baseline using ultrasound pa-
chymetry (Allergan Humphrey 850, Carl Zeiss Meditec, Dublin,
CA, USA). Another subset of participants from RS-I, RS-II and
RS-III underwent CCT measurements at follow-up using a non-
contact biometer (Lenstar LS900, Haag-Streit, Köniz, Switzer-
land). Other ophthalmic baseline and follow-up examinations,
which are still ongoing, were described previously (30). DNA
was isolated fromwhole blood according to standard procedures.
Genotyping of SNPswas performedusing the Illumina Inﬁnium II
HumanHap550 array (RS-I), the Illumina Inﬁnium HumanHap
550-Duo array (RS-I, RS-II) and the Illumina Inﬁnium Human
610-Quad array (RS-I, RS-III). Samples with low call rate
(<97.5%), with excess autosomal heterozygosity (>0.336) or with
sex-mismatch were excluded, as were outliers identiﬁed by the
identity-by-state clustering analysis (outliers were deﬁned as
being >3 standard deviation (SD) frompopulationmean or having
identity-by-state probabilities >97%). A set of genotyped input
SNPs with call rate >98%, MAF > 0.001 and Hardy–Weinberg equi-
librium (HWE) P-value > 10−6 was used for imputation. The Mar-
kov Chain Haplotyping (MACH) package version 1.0 software
(Rotterdam, The Netherlands; imputed to plus strand of NCBI
build 37, 1000 Genomes phase I version 3) and minimac version
2012.8.6 were used for the analysis. GWAS analyses were per-
formed using the ProbABEL package (31). The analyses were ad-
justed for age, sex and the ﬁrst ﬁve principal components. The
Rotterdam Study has been approved by the institutional review
board (Medical Ethics Committee) of the Erasmus Medical Center
and by the review board of The Netherlands Ministry of Health,
Welfare and Sports.
Brisbane Adolescent Twins Study and Twins Eye
Study in Tasmania
The Australian Twin Eye Study comprises participants examined
as part of TEST or BATS. In most participants, the IOP was mea-
sured with the TONO-PEN XL (Reichert, Inc., New York, NY, USA)
(32). The Australian twin cohorts were genotyped on the Illumina
Human Hap610W Quad array. The inclusion criteria for the SNPs
were a MAF > 0.01, HWE P-value ≥ 10−6 and a SNP call rate >95%
or Illumina Beadstudio Gencall Score ≥0.7, resulting in 543 862
SNPs. Imputation was done with reference to the August 4, 2010
version of the publicly released 1000 Genomes Project European
genotyping usingMACH. For BATS data, 1152 people from517 fam-
ilies were included in the analyses. For TEST data, 663 individuals
from 350 families were included. Association analyses were
performed in Merlin (http://www.sph.umich.edu/csg/abecasis/
merlin/) by using the –fastassoc option. Ancestry, initially deter-
mined through self-reporting, was veriﬁed through Principal Com-
ponent decomposition. The analyses were adjusted for age, sex,
the technique of IOPmeasurement and the ﬁrst ﬁve principal com-
ponents. The studieswere approved by the human ethics commit-
tees of the University of Tasmania, Royal Victorian Eye and Ear
Hospital, and Queensland Institute of Medical Research.
Blue Mountains Eye Study
The Blue Mountains Eye Study is a population-based cohort
study of common eye diseases in older Australians living in the
Blue Mountains region, west of Sydney, Australia. IOP was mea-
sured using Goldmann applanation tonometry (Haag-Streit,
Bern, Switzerland) (33). DNA was extracted from whole blood
and quality was validated by Sequenom iPLEX assay. Genotyping
was performed on the Illumina Inﬁnium platform using the Hu-
man660W-Quad, a Wellcome Trust Case Control Consortium 2
designed custom chip containing Human550 probes with 60 000
additional probes to capture common copy-number variations
from the Structural Variation Consortium (34). Genotyped data
were ﬁltered to include SNPs with genotyping rate ≥0.97, MAF≥
1%, HWE P-value ≥ 10−6. Samples with call rates <95% were ex-
cluded from analysis. Relatedness ﬁltering based on estimated
identity by descentwas performed, so that no pairs of individuals
sharedmore than 20% of their genome. Ancestry outliers with >6
SD from 1000 Genomes northern European ancestry samples
were removed. The IMPUTE2 software was used for imputation
of data on 1000Genomes phase 1 release version 3 (35,36). The as-
sociation test was performed using SNPTEST _v2.5-beta4 (37,38).
The analyseswere adjusted for age, sex and the ﬁrst ﬁve principal
components. The study was approved by the Human Research
Ethics Committees of the University of Sydney and Sydney
West Area Health Service.
Raine
The Western Australian Pregnancy Cohort (Raine) study is an
ongoing prospective cohort study of pregnancy, childhood,
2694 | Human Molecular Genetics, 2015, Vol. 24, No. 9
adolescence and young adulthood in Perth, Western Australia
(39). At the initiation of the study, 2900 pregnant womenwere re-
cruited at 16–18 weeks gestation from the state’s largest public
women’s hospital and surrounding private practices for a rando-
mized clinical trial investigating effects of intensive ultrasound
and Doppler studies in pregnancy outcomes. Following this
study, the offspring of the recruited individuals have been evalu-
ated in detail during childhood and adolescence. At the 20-year
review of the cohort, Raine participants underwent a compre-
hensive ocular examination for the ﬁrst time (40). As part of
this examination, IOP was measured using an Icare TAO1i Ton-
ometer (Icare Finland Oy, Helsinki, Finland). DNA samples and
consents for GWAS studies were available from the previous as-
sessments. Genotype data were generated using the genome-
wide Illumina 660 Quad Array at the Centre for Applied Genomics
(Toronto, Ontario, Canada). Relatedness ﬁltering based on esti-
mated identity by descent was performed, so that no pairs of indi-
viduals shared more than 20% of their genome. We also excluded
people who had a high degree of missing genotyping data (>3%).
The data were ﬁltered for a HWE P-value > 1 × 10−6, SNP call rate
>95% and a MAF > 0.01. GWAS imputation was performed in the
MACH v1.0.16 software using the 23 November 2010 version of
the 1000 Genome Project European genotyping. The association
analyses were adjusted for age, sex and the ﬁrst two principal
components. This study was approved by the Human Research
Ethics Committee of the University of Western Australia.
Australian and New Zealand Registry of Advanced
Glaucoma
ANZRAG recruits cases of advanced glaucoma Australia‐wide
through ophthalmologist referral. The cohort also included parti-
cipants enrolled in the Glaucoma Inheritance Study in Tasmania
(GIST) who met the criteria for ANZRAG. This cohort has been
described previously (9). Advanced POAGwas deﬁned as best‐cor-
rected visual acuity worse than 6/60 due to POAG, or a reliable
24‐2 Visual Field with a mean deviation of worse than −22 db or
at least two out of four central ﬁxation squares affected with a
Pattern SD of <0.5%. The less severely affected eye was also
required to have signs of glaucomatous disc damage. Clinical ex-
clusion criteria for this advanced POAG study were: (i) pseudoex-
foliation or pigmentary glaucoma, (ii) angle closure or mixed
mechanism glaucoma; (iii) secondary glaucoma due to aphakia,
rubella, rubeosis or inﬂammation; (iv) infantile glaucoma and
(v) glaucoma in the presence of a known associated syndrome.
The ANZRAG cohort included 1155 ANZRAG glaucoma cases
and 1992 controls genotyped on Illumina Omni1M or OmniEx-
press arrays and imputed against 1000 Genomes Phase 1
Europeans. The case set included all samples from the previously
published GWAS (9). Controls were drawn from the Australian
Cancer Study (225 oesophageal cancer cases, 317 Barrett’s oe-
sophagus cases and 552 controls) or from a study of inﬂamma-
tory bowel diseases (303 cases and 595 controls). The quality
control methods were performed in PLINK by removing indivi-
duals with more than 3% missing genotypes, SNPs with call
rate <97%, MAF <0.01 and HWE P-value < 0.0001 in controls and
HWE P-value < 5 × 10−10 in cases (41). The same quality control
protocol was used before merging the cases and controls to
avoid mismatches between the merged data sets. After merging,
the genotypes for 569 249 SNPs common to the arrays were taken
forward for analysis. Relatedness ﬁltering based on estimated
identity by descentwas performed, so that no pairs of individuals
shared more than 20% of their genome. Principal components
were computed for all participants and reference samples of
known northern European ancestry (1000G British, CEU and
Finland participants) using the smartpca package from EIGEN-
SOFT software (42,43). Participants with principal component
1 or 2 values >6 SD from the known northern European ancestry
group were excluded. Imputation was conducted using IMPUTE2
in 1-Mb sections, with the 1000 Genomes phase 1 Europeans
(March 2012 release) used as the reference panel (35,36). SNPs
with imputation quality score >0.8 and MAF > 0.01 were carried
forward for analysis. Association testing on the imputed data
was performed in SNPTEST _v2.5-beta3 using an additive model
(-frequentist 1) and full dosage scores (-method expected) with
sex and the ﬁrst six principal components ﬁtted as covariates
(37,38). All were Australians of European ancestry. Approval
was obtained from the Human Research Ethics Committees of
Southern Adelaide Health Service/Flinders University, University
of Tasmania, QIMR Berghofer Institute of Medical Research
(Queensland Institute of Medical Research) and the Royal Victor-
ian Eye and Ear Hospital.
Peak IOP measures were available for 1039 of the 1155 cases
in the ANZRAG cohort. Of these cases, 330 (31.8%) had NTG (IOP
≤ 21 mmHg) and 709 (68.2%) had HTG (IOP >21 mmHg). Associ-
ation testing for NTG and HTG was performed in SNPTEST
_v2.5-beta3 as explained above, using 1992 shared population
controls.
Erasmus Rucphen Family study and Genetic
Research in Isolated Populations programme
The ERF study is a family‐based cohort in a genetically isolated
population in the southwest of the Netherlands with over 3000
participants aged between 18 and 86 years (44,45). In the region
of the ERF population, a total of 110 patients with glaucoma
who did not participate in the ERF study were recruited in
three local hospitals. Their visual ﬁelds were tested with
standard automated perimetry (Humphrey Field Analyzer
c24-2 SITA Standard test programme) or the Octopus 101 (G2
program with TOP strategy) (Haag-Streit, Bern, Switzerland).
The diagnosis of glaucoma was made by the patient’s ophthal-
mologist and conﬁrmed by a glaucoma specialist (HGL). It was
based on a glaucomatous appearance of the optic disc (notching
or thinning of the neuroretinal rim), combined with a matching
glaucomatous visual ﬁeld defect, and open-angles seen by gonio-
scopy. Classiﬁcation of HTG (IOP > 21 mmHg) and NTG (IOP ≤ 21
mmHg) was based on IOP at the time of diagnosis. Participants
from the ERF study were used as the control group (n = 2125).
Genotyping was performed with the 318 K array of the Illumina
Inﬁnium II whole-genome genotyping assay (HumanHap300-2).
Samples with low call rate (<97.5%), with excess autosomal he-
terozygosity (>0.336) or with sex‐mismatch were excluded. A set
of genotyped input SNPs with call rate >98%, with MAF > 0.01
and with HWE P-value > 10−6 was used for imputation. We used
the MACH package version 1.0.18.c software (Rotterdam, The
Netherlands; imputed to plus strand of NCBI build 37, 1000 Ge-
nomes Phase I version 3) and minimac version 2012.8.15 for the
analyses. Association tests were performed using the ProbABEL
package (31). The analyseswere adjusted for age and sex. Allmea-
surements in these studies were conducted after theMedical Eth-
ics Committee of the Erasmus University had approved the study
protocols.
Expression data
We investigated the expression proﬁle of several genes using
NCBI’s UniGene (46), which is an organized view of the
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transcriptome that evaluates semi-quantitatively the EST calcu-
lated as the number of transcripts permillion (available online at
http://www.ncbi.nlm.nih.gov/unigene/). The EST data for ‘Break-
down by body site’ that show the approximate gene expression
pattern in different tissues were chosen.
Expression of genes in eye tissues was evaluated using two
databases: the EyeBrowse and the Ocular Tissue Database. The
EyeBrowse is a customized eye-centric version of the UCSC
Genome Browser, which includes (A) eye-derived ESTs from the
National Eye Institute (47) and (B) the EyeSage project (48,49).
The EyeBrowse is available at http://eyebrowse.cit.nih.gov/. We
only selected human data. In the Ocular Tissue Database, the
gene expression is indicated as Affymetrix Probe Logarithmic
Intensity Error (PLIER) normalized value. The PLIER normaliza-
tion method was described by Wagner et al. (50). The Ocular Tis-
sue Database is available at https://genome.uiowa.edu/otdb/.
Ensembl Genome Browser
The Ensembl Genome Browser release version 77 was used to
investigate regulatory variants in genome-wide signiﬁcant
regions (51).
Ingenuity Pathway Analysis
Network map was created using the IPA software (Ingenuity Sys-
tems, http://www.ingenuity.com, Redwood City, CA, USA), where
(i) ARHGEF12, (ii) known IOP-associated genes (ABO and FNDC3B),
(iii) known genes associated with both IOP and POAG (ABCA1,
CAV1/CAV2, GAS7 and TMCO1) as well as (iv) known genes
involved in familial forms of glaucoma (OPTN, TMCO1, WDR36)
were selected. The ‘Path explorer’ function (shortest + 1) was
used to map protein–protein interactions between ARHGEF12
and the rest of included genes. All direct and indirect interactions
are supported by at least one reference from the literature, a text-
book or canonical information stored in the Ingenuity Pathways
Knowledge Base.
Statistical analysis
We used themean IOP of the right and left eye for the analysis. If
IOPwasmissing for one eye, the IOPof the other eyewas used. For
participants receiving IOP-loweringmedication, we added 30% to
the IOP measurement to estimate a pre-medication IOP value
(52). Participants who underwent IOP-lowering laser or surgery
were excluded from the analysis. GWAS was performed on each
individual study as described above under the assumption of
an additive model for the effect of the risk allele. In a secondary
analysis in the discovery phase, CCT was included as an extra
covariate. We used METAL software to carry out an inverse vari-
ance weighted ﬁxed-effect meta-analysis between RS-I and RS-II
(53). SNPs with MAF <0.01 or with imputation quality score
R2 < 0.5 were excluded. For the meta-analysis of RS-I and RS-II,
a P-value of <5.0 × 10−8 (threshold of genome-wide signiﬁcance)
was considered statistically signiﬁcant. Next,we validated the as-
sociation results of the SNPs that reached genome-wide signiﬁ-
cance in ﬁve other studies (BMES, BATS, Raine, RS-III and TEST).
In the validation phase, a P-value of <0.05 was considered statis-
tically signiﬁcant. Furthermore, in the discovery and validation
cohorts, we meta-analysed all the SNPs with P-value < 5.0 × 10−5
in the region that reached genome-wide signiﬁcance in the dis-
covery cohort. We calculated the explained variance (R2) of IOP
by the new SNPs in RS-I and RS-II. In the ﬁrst model, we calcu-
lated the explained variance for themost signiﬁcantly associated
SNP. Next, we added SNPs located within a regulatory element or
all SNPswith P-value < 5.0 × 10−5 to themodel. The nestedmodels
were compared using an F-test. Finally, we investigated the effect
of the genome-wide signiﬁcant SNPs on POAG in ANZRAG and
ERF. A Manhattan plot, regional plots and forest plots were
made using R (54) and LocusZoom (55).
Supplementary Material
Supplementary Material is available at HMG online.
Acknowledgements
Wewould like to thank the contributions of all study participants
and staff at the recruitment centers.
Conﬂict of Interest statement. None declared.
Funding
S.M. is supported by Australian Research Council (ARC) and Aus-
tralian National Health & Medical Research Council (NHMRC)
Fellowships.
Erasmus Rucphen Family (ERF) Study and Rotterdam
Study
The Rotterdam Study and ERF were supported by the Nether-
lands Organisation of Scientiﬁc Research (NWO; 91111025); Eras-
mus Medical Center and Erasmus University, Rotterdam, The
Netherlands; Netherlands Organization for Health Research
and Development (ZonMw); UitZicht; the Research Institute for
Diseases in the Elderly; the Ministry of Education, Culture and
Science; the Ministry for Health, Welfare and Sports; the Euro-
pean Commission (DG XII); the Municipality of Rotterdam; the
Netherlands Genomics Initiative/NWO; Center for Medical Sys-
temsBiologyofNGI; Stichting Lijf en Leven; StichtingOogfondsNe-
derland; Landelijke Stichting voor Blinden en Slechtzienden;
Algemene Nederlandse Vereniging ter Voorkoming van Blindheid;
Medical Workshop; Heidelberg Engineering; Topcon Europe BV.
Henriët Springelkamp is supported by the NWO Graduate Pro-
gramme 2010 BOO (022.002.023), by Prins Bernhard Cultuurfonds
(Cultuurfondsbeurs from Jan de Ruijsscher/Pia Huisman fonds)
and by Novartis Pharma B.V. We acknowledge the contribution of
Ada Hooghart, Corina Brussee, Riet Bernaerts-Biskop, Patricia van
Hilten, Pascal Arp, Jeanette Vergeer and Maarten Kooijman.
The generation and management of GWAS genotype data for
theRotterdamStudy is supportedby theNetherlandsOrganisation
of Scientiﬁc Research NWO Investments (nr. 175.010.2005.011,
911-03-012). This study is funded by the Research Institute
for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands
Genomics Initiative (NGI)/Netherlands Organisation for Scientiﬁc
Research (NWO) project nr. 050-060-810. We thank Pascal Arp,
Mila Jhamai, Marijn Verkerk, Lizbeth Herrera and Marjolein
Peters for their help in creating the GWAS database, and Karol
Estrada and Maksim V. Struchalin for their support in creation
and analysis of imputed data.
The authors are grateful to the study participants, the staff
from the Rotterdam Study and the participating general practi-
tioners and pharmacists.
Australian and New Zealand Registry of Advanced
Glaucoma (ANZRAG)
Support for recruitment of ANZRAG was provided by the Royal
Australian and New Zealand College of Ophthalmology
2696 | Human Molecular Genetics, 2015, Vol. 24, No. 9
(RANZCO) Eye Foundation. Genotyping was funded by the Na-
tional Health and Medical Research Council of Australia
(#535074 and #1023911). Thisworkwas also supported by funding
from the BrightFocus Foundation and a Ramaciotti Establish-
ment Grant. The authors acknowledge the support of Ms Bron-
wyn Usher-Ridge in patient recruitment and data collection,
and Dr Patrick Danoy and Dr Johanna Hadler for genotyping.
Controls for the ANZRAG discovery cohort were drawn from
the Australian Cancer Study, the Study of Digestive Health and
from a study of inﬂammatory bowel diseases. The Australian
Cancer Study was supported by the Queensland Cancer Fund
and the National Health and Medical Research Council
(NHMRC) of Australia (Program no. 199600, awarded to David
C. Whiteman, Adele C. Green, Nicholas K. Hayward, Peter
G. Parsons, David M. Purdie, and Penelope M. Webb). The Study
of Digestive Health was supported by grant number 5 RO1 CA
001833 from the National Cancer Institute (awarded to David
C.Whiteman).We acknowledge David C.Whiteman and Graham
Radford-Smith for providing access to these control samples.
The Barrett’s and Esophageal Adenocarcinoma Genetic Suscep-
tibility Study (BEAGESS) sponsored the genotyping of oesophageal
cancer and Barrett’s oesophagus cases, which were used as un-
screened controls in the ANZRAG discovery cohort. BEAGESS was
funded by grant R01 CA136725 from the National Cancer Institute.
Blue Mountains Eye Study
BMESwas supported by the Australian National Health &Medical
Research Council (NH&MRC), Canberra Australia (974159, 211069,
457349, 512423, 475604, 529912); the Centre for Clinical Research
Excellence (Translational Clinical Research in Major Eye Dis-
eases, 519923); NH&MRC research fellowships (358702, 632909
to J.J.W); and the Wellcome Trust, UK as part of Wellcome Trust
Case Control Consortium 2 (A. Viswanathan, P. McGufﬁn,
P. Mitchell, F. Topouzis, P. Foster) for genotyping costs of the en-
tire BMES population (085475/B/08/Z, 085475/Z/08/Z, 076113).
In addition to three co-authors (A.C.V., P.M. and J.J.W.), the
BMES GWAS team includes Elena Rochtchina from the Centre
for Vision Research, Department of Ophthalmology and West-
meadMillennium Institute University of Sydney (NSWAustralia);
John Attia, Rodney Scott, Elizabeth G. Holliday from the Univer-
sity of Newcastle (Newcastle, NSWAustralia); Paul N. Baird and
Jing Xie from the Centre for Eye Research Australia, University
of Melbourne; Michael T. Inouye, Medical Systems Biology, De-
partment of Pathology and Department of Microbiology and Im-
munology, University ofMelbourne (Victoria, Australia); andTien
Y. Wong and Xueling Sim from the National University of Singa-
pore, Singapore.
The Centre for Eye Research Australia receives Operational In-
frastructure Support from the Victorian government.
Western Australian Pregnancy Cohort (Raine) Study
Coremanagement of the Raine Study is funded by the University
of Western Australia, Telethon Kids Institute, Raine Medical Re-
search Foundation, UWA Faculty of Medicine, Dentistry and
Health Sciences, Women’s and Infant’s Research Foundation
andCurtin University. Genotypingwas funded byNHMRC project
grant 572613 (CI-A Pennell). Support for the Raine Eye Health Study
was provided byNHMRCGrant 1021105 (CI-AMackey), Lions Eye In-
stitute, the Australian Foundation for the Prevention of Blindness,
Ophthalmic Research Institute of Australia and Alcon Research In-
stitute. The Raine Eye Health Study authors thank the Raine Eye
Health Study participants and their families. They also thank the
Raine Study management team, Craig E. Pennell, and the teams
at TKI and LEI for cohort coordination and data collection, particu-
larly: Charlotte McKnight, Seyhan Yazar, Hannah Forward, Wei
Ang, Alex Tan, Alla Soloshenko, Sandra Oates and Diane Wood.
Twins Eye Study in Tasmania (TEST) and Brisbane
Adolescent Twin Study (BATS)
Genotyping for part of the Australian twin samplewas funded by
an NHMRC Medical Genomics Grant. Genotyping for the remain-
der of twin controls was performed by the National Institutes of
Health (NIH) Center for Inherited Research (CIDR) as part of an
NIH/National Eye Institute (NEI) grant 1RO1EY018246, and we
are grateful to Dr Camilla Day and staff. We thank Sullivan Nico-
laides and Queensland Medical Laboratory for pro bono collec-
tion and delivery of blood samples and other pathology
services for assistance with blood collection. The QIMR twin
studies were supported by grants from the National Health
and Medical Research Council (NHMRC) of Australia (241944,
339462, 389927, 389875, 389891, 389892, 389938, 443036, 442915,
442981, 496610, 496739, 552485, 552498), the Cooperative Re-
search Centre for Discovery of Genes for Common Human Dis-
eases (CRC), Cerylid Biosciences (Melbourne) and donations
from Neville and Shirley Hawkins. We thank Grant Montgomery,
Margaret J. Wright, Megan J. Campbell, Anthony Caracella, Scott
Gordon, Dale R. Nyholt, Anjali K. Henders, B. Haddon, D. Smyth,
H. Beeby, O. Zheng, B. Chapman for their input into project man-
agement, databases, sample processing and genotyping. We are
grateful to the many research assistants and interviewers for
assistance with the studies contributing to the QIMR twin
collection.
References
1. Wolfs, R.C., Klaver, C.C., Ramrattan, R.S., van Duijn, C.M.,
Hofman, A. and de Jong, P.T. (1998) Genetic risk of primary
open-angle glaucoma. Population-based familial aggregation
study. Arch. Ophthalmol., 116, 1640–1645.
2. Kubota, R., Noda, S., Wang, Y., Minoshima, S., Asakawa, S.,
Kudoh, J., Mashima, Y., Oguchi, Y. and Shimizu, N. (1997) A
novel myosin-like protein (myocilin) expressed in the con-
necting cilium of the photoreceptor: molecular cloning, tis-
sue expression, and chromosomal mapping. Genomics, 41,
360–369.
3. Monemi, S., Spaeth, G., DaSilva, A., Popinchalk, S., Ilitchev, E.,
Liebmann, J., Ritch, R., Heon, E., Crick, R.P., Child, A. et al.
(2005) Identiﬁcation of a novel adult-onset primary open-
angle glaucoma (POAG) gene on 5q22.1. Hum. Mol. Genet., 14,
725–733.
4. Rezaie, T., Child, A., Hitchings, R., Brice, G., Miller, L., Coca-
Prados, M., Heon, E., Krupin, T., Ritch, R., Kreutzer, D. et al.
(2002) Adult-onset primary open-angle glaucoma caused by
mutations in optineurin. Science, 295, 1077–1079.
5. Sarfarazi, M., Child, A., Stoilova, D., Brice, G., Desai, T., Trifan,
O.C., Poinoosawmy, D. and Crick, R.P. (1998) Localization
of the fourth locus (GLC1E) for adult-onset primary open-
angle glaucoma to the 10p15-p14 region. Am. J. Hum. Genet.,
62, 641–652.
6. Shefﬁeld, V.C., Stone, E.M., Alward,W.L., Drack, A.V., Johnson,
A.T., Streb, L.M. and Nichols, B.E. (1993) Genetic linkage of
familial open angle glaucoma to chromosome 1q21-q31.
Nat. Genet., 4, 47–50.
7. Stone, E.M., Fingert, J.H., Alward, W.L., Nguyen, T.D., Polans-
ky, J.R., Sunden, S.L., Nishimura, D., Clark, A.F., Nystuen, A.,
Human Molecular Genetics, 2015, Vol. 24, No. 9 | 2697
Nichols, B.E. et al. (1997) Identiﬁcation of a gene that causes
primary open angle glaucoma. Science, 275, 668–670.
8. Gharahkhani, P., Burdon, K.P., Fogarty, R., Sharma, S., Hewitt,
A.W.,Martin, S., Law,M.H., Cremin, K., Bailey, J.N., Loomis, S.J.
et al. (2014) Common variants near ABCA1, AFAP1 and GMDS
confer risk of primary open-angle glaucoma. Nat. Genet., 46,
1120–1125.
9. Burdon, K.P.,Macgregor, S., Hewitt, A.W., Sharma, S., Chidlow,
G., Mills, R.A., Danoy, P., Casson, R., Viswanathan, A.C., Liu, J.
Z. et al. (2011) Genome-wide association study identiﬁes sus-
ceptibility loci for open angle glaucoma at TMCO1 and
CDKN2B-AS1. Nat. Genet., 43, 574–578.
10. Ramdas, W.D., van Koolwijk, L.M., Lemij, H.G., Pasutto, F.,
Cree, A.J., Thorleifsson, G., Janssen, S.F., Jacoline, T.B.,
Amin, N., Rivadeneira, F. et al. (2011) Common genetic var-
iants associated with open-angle glaucoma. Hum. Mol.
Genet., 20, 2464–2471.
11. Thorleifsson, G., Walters, G.B., Hewitt, A.W., Masson, G., Hel-
gason, A., DeWan, A., Sigurdsson, A., Jonasdottir, A., Gud-
jonsson, S.A., Magnusson, K.P. et al. (2010) Common
variants near CAV1 and CAV2 are associated with primary
open-angle glaucoma. Nat. Genet., 42, 906–909.
12. van Koolwijk, L.M., Ramdas, W.D., Ikram, M.K., Jansonius, N.
M., Pasutto, F., Hysi, P.G., Macgregor, S., Janssen, S.F., Hewitt,
A.W., Viswanathan, A.C. et al. (2012) Common genetic deter-
minants of intraocular pressure and primary open-angle
glaucoma. PLoS Genet., 8, e1002611.
13. Sanﬁlippo, P.G., Hewitt, A.W., Hammond, C.J. and Mackey, D.
A. (2010) The heritability of ocular traits. Surv. Ophthalmol., 55,
561–583.
14. van Koolwijk, L.M., Despriet, D.D., van Duijn, C.M., Pardo Cor-
tes, L.M., Vingerling, J.R., Aulchenko, Y.S., Oostra, B.A., Klaver,
C.C. and Lemij, H.G. (2007) Genetic contributions to glau-
coma: heritability of intraocular pressure, retinal nerve ﬁber
layer thickness, and optic disc morphology. Invest. Ophthal-
mol. Vis. Sci., 48, 3669–3676.
15. Nag, A., Venturini, C. and Small, K.S., International Glaucoma
Genetics, C., Young, T.L., Viswanathan, A.C., Mackey, D.A.,
Hysi, P.G. and Hammond, C. (2014) A genome-wide associ-
ation study of intra-ocular pressure suggests a novel associ-
ation in the gene FAM125B in the TwinsUK cohort. Hum.
Mol. Genet., 23, 3343–3348.
16. Hysi, P.G., Cheng, C.Y., Springelkamp, H., Macgregor, S., Bai-
ley, J.N., Wojciechowski, R., Vitart, V., Nag, A., Hewitt, A.W.,
Hohn, R. et al. (2014) Genome-wide analysis ofmulti-ancestry
cohorts identiﬁes new loci inﬂuencing intraocular pressure
and susceptibility to glaucoma. Nat. Genet., 46, 1126–1130.
17. Fukuhara, S., Chikumi, H. and Gutkind, J.S. (2000) Leukemia-
associated Rho guanine nucleotide exchange factor (LARG)
links heterotrimeric G proteins of the G(12) family to Rho.
FEBS Lett., 485, 183–188.
18. Pattabiraman, P.P., Maddala, R. and Rao, P.V. (2014) Regulation
of plasticity and ﬁbrogenic activity of trabecular meshwork
cells by Rho GTPase signaling. J. Cell. Physiol., 229, 927–942.
19. Kumar, J. and Epstein, D.L. (2011) Rho GTPase-mediated cyto-
skeletal organization in Schlemm’s canal cells play a critical
role in the regulation of aqueous humor outﬂow facility. J.
Cell. Biochem., 112, 600–606.
20. Wang, J., Liu, X. and Zhong, Y. (2013) Rho/Rho-associated
kinase pathway in glaucoma (Review). Int. J. Oncol., 43, 1357–
1367.
21. Okuhira, K., Fitzgerald, M.L., Tamehiro, N., Ohoka, N., Suzuki,
K., Sawada, J., Naito, M. and Nishimaki-Mogami, T. (2010)
Binding of PDZ-RhoGEF to ATP-binding cassette transporter
A1 (ABCA1) induces cholesterol efﬂux through RhoA activa-
tion and prevention of transporter degradation. J. Biol.
Chem., 285, 16369–16377.
22. Brumby, A.M., Goulding, K.R., Schlosser, T., Loi, S., Galea, R.,
Khoo, P., Bolden, J.E., Aigaki, T., Humbert, P.O. and Richard-
son, H.E. (2011) Identiﬁcation of novel Ras-cooperating onco-
genes in Drosophila melanogaster: a RhoGEF/Rho-family/JNK
pathway is a central driver of tumorigenesis. Genetics, 188,
105–125.
23. Barrett, K., Leptin, M. and Settleman, J. (1997) The Rho GTPase
andaputative RhoGEFmediate a signaling pathway for the cell
shape changes in Drosophila gastrulation. Cell, 91, 905–915.
24. Hacker, U. and Perrimon, N. (1998) DRhoGEF2 encodes a
member of the Dbl family of oncogenes and controls cell
shape changes during gastrulation in Drosophila. Genes Dev.,
12, 274–284.
25. Hariharan, I.K., Hu, K.Q., Asha, H., Quintanilla, A., Ezzell, R.M.
and Settleman, J. (1995) Characterization of rho GTPase fam-
ily homologues in Drosophila melanogaster: overexpressing
Rho1 in retinal cells causes a late developmental defect.
EMBO J., 14, 292–302.
26. Mikelis, C.M., Palmby, T.R., Simaan, M., Li, W., Szabo, R.,
Lyons, R., Martin, D., Yagi, H., Fukuhara, S., Chikumi, H.
et al. (2013) PDZ-RhoGEF and LARG are essential for embry-
onic development and provide a link between thrombin
and LPA receptors and Rho activation. J. Biol. Chem., 288,
12232–12243.
27. Cabral, A., Fischer, D.F., Vermeij, W.P. and Backendorf, C.
(2003) Distinct functional interactions of human Skn-1
isoforms with Ese-1 during keratinocyte terminal differenti-
ation. J. Biol. Chem., 278, 17792–17799.
28. Lu, Y., Vitart, V., Burdon, K.P., Khor, C.C., Bykhovskaya, Y.,
Mirshahi, A., Hewitt, A.W., Koehn, D., Hysi, P.G., Ramdas, W.
D. et al. (2013) Genome-wide association analyses identify
multiple loci associated with central corneal thickness and
keratoconus. Nat. Genet., 45, 155–163.
29. Hofman, A., Darwish Murad, S., van Duijn, C.M., Franco, O.H.,
Goedegebure, A., Ikram, M.A., Klaver, C.C., Nijsten, T.E., Pe-
eters, R.P., Stricker, B.H. et al. (2013) The Rotterdam Study:
2014 objectives and design update. Eur. J. Epidemiol., 28, 889–
926.
30. Wolfs, R.C., Borger, P.H., Ramrattan, R.S., Klaver, C.C., Huls-
man, C.A., Hofman, A., Vingerling, J.R., Hitchings, R.A. and
de Jong, P.T. (2000) Changing views on open-angle glaucoma:
deﬁnitions and prevalences—the Rotterdam Study. Invest.
Ophthalmol .Vis. Sci., 41, 3309–3321.
31. Aulchenko, Y.S., Struchalin, M.V. and van Duijn, C.M. (2010)
ProbABEL package for genome-wide association analysis of
imputed data. BMC Bioinformatics, 11, 134.
32. Mackey, D.A., Mackinnon, J.R., Brown, S.A., Kearns, L.S.,
Ruddle, J.B., Sanﬁlippo, P.G., Sun, C., Hammond, C.J., Young,
T.L., Martin, N.G. et al. (2009) Twins eye study in Tasmania
(TEST): rationale and methodology to recruit and examine
twins. Twin. Res. Hum. Genet., 12, 441–454.
33. Mitchell, P., Smith, W., Attebo, K. and Wang, J.J. (1995) Preva-
lence of age-related maculopathy in Australia. The Blue
Mountains Eye Study. Ophthalmology, 102, 1450–1460.
34. Conrad, D.F., Pinto, D., Redon, R., Feuk, L., Gokcumen, O.,
Zhang, Y., Aerts, J., Andrews, T.D., Barnes, C., Campbell, P.
et al. (2010) Origins and functional impact of copy number
variation in the human genome. Nature, 464, 704–712.
35. Howie, B., Marchini, J. and Stephens, M. (2011) Genotype
imputation with thousands of genomes. G3 (Bethesda), 1,
457–470.
2698 | Human Molecular Genetics, 2015, Vol. 24, No. 9
36. Howie, B.N., Donnelly, P. andMarchini, J. (2009) A ﬂexible and
accurate genotype imputation method for the next gener-
ation of genome-wide association studies. PLoS. Genet., 5,
e1000529.
37. Marchini, J. and Howie, B. (2010) Genotype imputation
for genome-wide association studies. Nat. Rev. Genet., 11,
499–511.
38. Wellcome Trust Case Control, C. (2007) Genome-wide associ-
ation study of 14,000 cases of seven common diseases and
3,000 shared controls. Nature, 447, 661–678.
39. McKnight, C.M., Newnham, J.P., Stanley, F.J., Mountain, J.A.,
Landau, L.I., Beilin, L.J., Puddey, I.B., Pennell, C.E. andMackey,
D.A. (2012) Birth of a cohort–the ﬁrst 20 years of the Raine
study. Med. J. Aust., 197, 608–610.
40. Yazar, S., Forward, H., McKnight, C.M., Tan, A., Soloshenko,
A., Oates, S.K., Ang, W., Sherwin, J.C., Wood, D., Mountain, J.
A. et al. (2013) Raine eye health study: design, methodology
and baseline prevalence of ophthalmic disease in a birth-co-
hort study of young adults. Ophthalmic. Genet., 34, 199–208.
41. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A.,
Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly, M.J. et al.
(2007) PLINK: a tool set forwhole-genomeassociationandpopu-
lation-based linkage analyses. Am. J. Hum. Genet., 81, 559–575.
42. Patterson, N., Price, A.L. and Reich, D. (2006) Population struc-
ture and eigenanalysis. PLoS. Genet., 2, e190.
43. Price, A.L., Patterson, N.J., Plenge, R.M., Weinblatt, M.E., Sha-
dick, N.A. and Reich, D. (2006) Principal components analysis
corrects for stratiﬁcation in genome-wide association stud-
ies. Nat. Genet., 38, 904–909.
44. Aulchenko, Y.S., Heutink, P., Mackay, I., Bertoli-Avella, A.M.,
Pullen, J., Vaessen, N., Rademaker, T.A., Sandkuijl, L.A., Car-
don, L., Oostra, B. et al. (2004) Linkage disequilibrium in
young genetically isolated Dutch population. Eur. J. Hum.
Genet., 12, 527–534.
45. Pardo, L.M., MacKay, I., Oostra, B., van Duijn, C.M. and
Aulchenko, Y.S. (2005) The effect of genetic drift in a young
genetically isolated population.Ann. Hum. Genet., 69, 288–295.
46. NCBI Resource Coordinators. (2015) Database resources of the
National Center for Biotechnology Information. Nucleic Acids
Res., 43, D6–D17.
47. Wistow, G., Peterson, K., Gao, J., Buchoff, P., Jaworski, C.,
Bowes-Rickman, C., Ebright, J.N., Hauser, M.A. and Hoover,
D. (2008) NEIBank: genomics and bioinformatics resources
for vision research. Mol. Vis., 14, 1327–1337.
48. Bowes Rickman, C., Ebright, J.N., Zavodni, Z.J., Yu, L., Wang,
T., Daiger, S.P., Wistow, G., Boon, K. and Hauser, M.A. (2006)
Deﬁning the human macula transcriptome and candidate
retinal disease genes using EyeSAGE. Invest. Ophthalmol. Vis.
Sci., 47, 2305–2316.
49. Liu, Y., Munro, D., Layﬁeld, D., Dellinger, A., Walter, J., Peter-
son, K., Rickman, C.B., Allingham, R.R. and Hauser, M.A.
(2011) Serial analysis of gene expression (SAGE) in normal
human trabecular meshwork. Mol. Vis., 17, 885–893.
50. Wagner, A.H., Anand, V.N., Wang, W.H., Chatterton, J.E., Sun,
D., Shepard, A.R., Jacobson, N., Pang, I.H., Deluca, A.P., Casa-
vant, T.L. et al. (2013) Exon-level expression proﬁling of ocular
tissues. Exp. Eye. Res., 111, 105–111.
51. Flicek, P., Amode, M.R., Barrell, D., Beal, K., Billis, K., Brent, S.,
Carvalho-Silva, D., Clapham, P., Coates, G., Fitzgerald, S. et al.
(2014) Ensembl 2014. Nucleic Acids Res., 42, D749–D755.
52. van der Valk, R., Webers, C.A., Schouten, J.S., Zeegers, M.P.,
Hendrikse, F. and Prins, M.H. (2005) Intraocular pressure-low-
ering effects of all commonly used glaucoma drugs: a meta-
analysis of randomized clinical trials. Ophthalmology, 112,
1177–1185.
53. Willer, C.J., Li, Y. and Abecasis, G.R. (2010) METAL: fast and
efﬁcient meta-analysis of genomewide association scans.
Bioinformatics, 26, 2190–2191.
54. R Core Team. (2014) R: a language and environment for
statistical computing. http://www.R-project.org.
55. Pruim, R.J.,Welch, R.P., Sanna, S., Teslovich, T.M., Chines, P.S.,
Gliedt, T.P., Boehnke, M., Abecasis, G.R. and Willer, C.J. (2010)
LocusZoom: regional visualization of genome-wide associ-
ation scan results. Bioinformatics, 26, 2336–2337.
Human Molecular Genetics, 2015, Vol. 24, No. 9 | 2699
